DiaMedica Therapeutics (DMAC) Enterprise Value (2017 - 2026)

DiaMedica Therapeutics has reported Enterprise Value for 10 years, with the latest figure at -$51.3 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value fell 41.33% year-over-year to -$51.3 million; the trailing twelve-month figure through Mar 2026 stood at -$51.3 million (down 41.33% YoY), and the FY2025 full-year result was -$59.9 million, down 35.66% from the prior year.
• Enterprise Value for Q1 2026 stood at -$51.3 million, up from -$59.9 million in the prior quarter.
• The five-year high for Enterprise Value was -$2.8 million in Q3 2022, with the low at -$59.9 million in Q4 2025.
• Historically, Enterprise Value has averaged -$39.8 million across 5 years, with a median of -$44.1 million in 2024.
• Annual changes were most pronounced in 2022 — Enterprise Value soared 94.22% — and 2023, when it sank 1571.4%.
• DiaMedica Therapeutics' Enterprise Value stood at -$33.5 million in 2022, then sank by 57.89% to -$52.9 million in 2023, then gained by 16.54% to -$44.1 million in 2024, then sank by 35.66% to -$59.9 million in 2025, then climbed by 14.29% to -$51.3 million in 2026.
• The last three Enterprise Value figures came in at -$51.3 million (Q1 2026), -$59.9 million (Q4 2025), and -$55.3 million (Q3 2025), per Business Quant data.